Analysts have slightly adjusted their price target for Indegene, lowering it from ₹609.57 to ₹608.14 as a result of modest revisions in growth and profitability assumptions.
What's in the News
- A board meeting is scheduled for October 30, 2025 to consider consolidated and standalone financial results as well as ESOP/RSU allotments (Board Meeting).
- The consulting practice is expanding to help life sciences organizations implement strategic and transformative solutions (Business Expansions).
- A strategic alliance has been formed with Datavant to improve patient recruitment for clinical trials by using advanced data enrichment on Indegene's platform (Strategic Alliances).
- A new center has opened in Pune to strengthen Indegene's capabilities by leveraging local technology, management, and medical talent (Business Expansions).
Valuation Changes
- Consensus Analyst Price Target has declined modestly from ₹609.57 to ₹608.14.
- Discount Rate has risen slightly, moving from 14.01% to 14.04%.
- Revenue Growth projections remain virtually unchanged at approximately 16.90%.
- Net Profit Margin has improved, increasing from 12.78% to 13.18%.
- Future P/E has decreased slightly, shifting from 35.22x to 33.94x.
Have other thoughts on Indegene?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.